Literature DB >> 30098710

The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.

Frediano Inzani1, Gianluigi Petrone2, Guido Rindi3.   

Abstract

Based on the 2010 version, the 2017 World Health Organization (WHO 2017) classification is for pancreatic neuroendocrine neoplasms (PanNEN). The WHO 2017 classification introduces the novel well-differentiated neuroendocrine tumor of high grade (NET G3). A sharp distinction between NET and poorly differentiated neuroendocrine carcinoma (NEC) is emphasized to highlight substantial biological differences. Further changes comprise the definition of mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN), to accommodate all grades of both neoplasm components, and the abolition of preneoplastic lesions given their rarity in the pancreas. The 2017 American Joint Cancer Committee classification (AJCC 2017) adopts such a classification for all digestive sites.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  American Joint Cancer Committee; Ki67; Neuroendocrine carcinoma; Neuroendocrine neoplasm; Neuroendocrine tumor; World Health Organization

Mesh:

Year:  2018        PMID: 30098710     DOI: 10.1016/j.ecl.2018.04.008

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  48 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

2.  Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.

Authors:  Junho Kang; Changhoon Yoo; Hee-Sang Hwang; Seung-Mo Hong; Kyu-Pyo Kim; Sun Young Kim; Yong-Sang Hong; Tae Won Kim; Baek-Yeol Ryoo
Journal:  Invest New Drugs       Date:  2018-12-10       Impact factor: 3.850

3.  Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.

Authors:  Marco Dioguardi Burgio; Jérome Cros; Nicola Panvini; Thomas Depoilly; Anne Couvelard; Philippe Ruszniewski; Louis de Mestier; Olivia Hentic; Alain Sauvanet; Safi Dokmak; Alex Faccinetto; Maxime Ronot; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2021-05-11       Impact factor: 5.315

4.  EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

Authors:  James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

5.  Magnetic resonance imaging radiomic analysis can preoperatively predict G1 and G2/3 grades in patients with NF-pNETs.

Authors:  Yun Bian; Jing Li; Kai Cao; Xu Fang; Hui Jiang; Chao Ma; Gang Jin; Jianping Lu; Li Wang
Journal:  Abdom Radiol (NY)       Date:  2020-08-17

6.  Histologic and molecular features of small well-differentiated pancreatic neuroendocrine tumors associated with the development of liver metastases.

Authors:  Paula Jiménez-Fonseca; Patricia Morales Del Burgo; Felipe Alvarez-Manceñido
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

7.  Mixed neuroendocrine nonneuroendocrine neoplasms of the pancreas: a case report and literature review of pancreatic mixed neuroendocrine nonneuroendocrine neoplasm.

Authors:  Fei Wang; Xin Lou; Yi Qin; Xiaowu Xu; Xianjun Yu; Dan Huang; Shunrong Ji
Journal:  Gland Surg       Date:  2021-12

Review 8.  Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.

Authors:  Namrata Vijayvergia; Arvind Dasari
Journal:  Curr Treat Options Oncol       Date:  2020-10-07

9.  Pathogenic ATM Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms.

Authors:  Hussein Nassereddine; Matthieu Chicaud; Khedidja Rebah; Nathalie Théou-Anton; Anne Sautet; Jacques Dermer; Anne Couvelard
Journal:  Endocr Pathol       Date:  2021-05-21       Impact factor: 3.943

10.  Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor - an update on neuroendocrine neoplasm's treatment: A case report.

Authors:  Oriol Mirallas; Nadia Saoudi; Diego Gómez-Puerto; Mar Riveiro-Barciela; Xavier Merino; Cristina Auger; Stefania Landolfi; Laia Blanco; Amparo Garcia-Burillo; Xavier Molero; Maria Teresa Salcedo-Allende; Jaume Capdevila
Journal:  World J Hepatol       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.